Smith & Nephew (LON:SN) Share Price Crosses Above Two Hundred Day Moving Average – Here’s Why

Smith & Nephew plc (LON:SN) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 1,297.06 and traded as high as GBX 1,307. Smith & Nephew shares last traded at GBX 1,306.50, with a volume of 2,454,084 shares traded.

Analyst Ratings Changes

Several research firms have recently weighed in on SN. Berenberg Bank reiterated a “hold” rating and set a GBX 1,300 price objective on shares of Smith & Nephew in a research report on Friday, January 23rd. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Smith & Nephew in a report on Friday, November 7th. Royal Bank Of Canada downgraded Smith & Nephew to a “sector perform” rating and dropped their price objective for the company from GBX 1,700 to GBX 1,350 in a research note on Wednesday, December 17th. Panmure Gordon restated a “hold” rating and set a GBX 1,200 target price on shares of Smith & Nephew in a research report on Tuesday, December 9th. Finally, Citigroup lifted their target price on Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the stock a “buy” rating in a report on Friday, October 31st. Two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of GBX 1,381.33.

Smith & Nephew Price Performance

The business has a 50-day moving average price of GBX 1,239.21 and a two-hundred day moving average price of GBX 1,297.06. The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22. The company has a market capitalization of £14.53 billion, a price-to-earnings ratio of 47.70, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.